Ethris

Evonik and Ethris enter strategic partnership to expand offerings for nucleic acid delivery

Developing and manufacturing innovative LNP delivery technology for respiratory medicine and beyond Expanding Evonik’s CDMO offerings, enabling efficient translation from concept to clinic Accelerating RNA-based therapeutic solutions for customers through co-development of products and formulation support. 9 September 2025 -- Essen/Munich, Germany -- Evonik, a global specialty chemicals company, and Ethris, a clinical-stage biotechnology company pioneering...

DIOSynVax and Ethris Publish Preclinical Proof of Concept for Their Broadly Protective Vaccine Technologies in Nature Biomedical Engineering

Successful vaccine candidate combining DIOSynVax's computational multi-virus vaccine antigen payload technology and Ethris’ proprietary non-immunogenic messenger RNA (SNIM mRNA) and lipidoid nanoparticle (SNaP LNP) platforms Data demonstrates broad in vivo immune responses against multiple sarbecocoronaviruses and SARS-CoV-2 variants 25 September 2023 – Munich, Germany and Cambridge, UK - Ethris GmbH, a leading biotechnology company pioneering...